Karen E. Hansen, M.D., M.S., of the University of Wisconsin School of Medicine and Public Health, Madison, and colleagues compared the effects of placebo, low -
dose cholecalciferol (a form of vitamin D) and high -
dose cholecalciferol on one - year changes on total TFCA, bone mineral density, sit - to - stand tests and muscle mass in 230 postmenopausal women (75 or younger) with vitamin D insufficiency.
They point out individuals only participated for one year and perhaps longer exposure to high -
dose cholecalciferol might yield greater effects on bone mineral density.
In a related Editor's Note, Deborah Grady, M.D., M.P.H., a deputy editor of JAMA Internal Medicine, writes: «It is possible that treatment beyond one year would result in better outcomes, but these data provide no support for use of higher -
dose cholecalciferol replacement therapy or indeed any dose of cholecalciferol compared with placebo.»
«Study results do not justify the common and frequently touted practice of administering high -
dose cholecalciferol to older adults to maintain serum 25 (OH) D [25 - hydroxyvitamin D] levels of 30 ng / mL or greater,» the study concludes.
Not exact matches
In the first group, 68 subjects received ready - to - mix, powdered vitamin D3 (
cholecalciferol, D - Rise sachets, USV Ltd., Mumbai, India) at a
dose of 60,000 International Units (IU) once weekly for eight weeks and then monthly.